UNIVERSITY OF WASHINGTON
πΊπΈUnited States
- Country
- πΊπΈUnited States
- Ownership
- Private
- Established
- 1861-01-01
- Employees
- 10K
- Market Cap
- -
Pembrolizumab With Rituximab or Obinutuzumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell Lymphoma
Phase 2
Active, not recruiting
- Conditions
- Recurrent Diffuse Large B-Cell LymphomaRecurrent Follicular LymphomaRefractory Diffuse Large B-Cell LymphomaRefractory Follicular Lymphoma
- Interventions
- Other: Laboratory Biomarker AnalysisBiological: PembrolizumabBiological: RituximabBiological: Obinutuzumab
- First Posted Date
- 2018-01-17
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 18
- Registration Number
- NCT03401853
- Locations
- πΊπΈ
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Treatment Navigation for Opioid Use Disorder
Not Applicable
Completed
- Conditions
- Opioid-use Disorder
- Interventions
- Other: ControlBehavioral: Treatment Navigation (Intervention)
- First Posted Date
- 2018-01-12
- Last Posted Date
- 2021-07-20
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 17
- Registration Number
- NCT03398265
- Locations
- πΊπΈ
DOC Community Field Office, Renton, Washington, United States
RESIST-2: 2nd-line ART for HIV-2 Infection
Not Applicable
Terminated
- Conditions
- HIV-2 Infection
- Interventions
- Diagnostic Test: HIV-2 Genotypic Drug Resistance Testing using DBS
- First Posted Date
- 2018-01-09
- Last Posted Date
- 2021-01-25
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 152
- Registration Number
- NCT03394196
- Locations
- πΈπ³
Clinique des Maladies Infectieuses Ibrahima DIOP Mar/CRCF, Centre Hospitalier Universitaire de Fann, Dakar, Senegal
πΈπ³Centre de Sante de Ziguinchor, Ziguinchor, Casamance, Senegal
High Throughput Drug Sensitivity and Genomics Data in Developing Individualized Treatment in Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia
Not Applicable
Active, not recruiting
- Conditions
- Plasma Cell LeukemiaRecurrent Multiple MyelomaRefractory Multiple Myeloma
- Interventions
- Procedure: Biospecimen CollectionDevice: High Throughput ScreeningOther: Laboratory Biomarker Analysis
- First Posted Date
- 2018-01-03
- Last Posted Date
- 2025-02-20
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 40
- Registration Number
- NCT03389347
- Locations
- πΊπΈ
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Dental Hygiene and Peri-Implant Tissues Homeostasis
Not Applicable
Completed
- Conditions
- Peri-Implantitis
- Interventions
- Other: Tooth-borne treatmentOther: Implant-specific treatment
- First Posted Date
- 2017-12-27
- Last Posted Date
- 2023-07-05
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 34
- Registration Number
- NCT03384446
- Locations
- πΊπΈ
UTHealth San Antonio, San Antonio, Texas, United States
πΊπΈUniversity of Washington, Department of Periodontics, Seattle, Washington, United States
Volunteer-Delivery of Behavioral Activation
Not Applicable
Completed
- Conditions
- Depression
- Interventions
- Behavioral: Volunteer-delivered Behavioral ActivationBehavioral: MSW-delivered Behavioral Activation
- First Posted Date
- 2017-12-13
- Last Posted Date
- 2020-10-26
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 55
- Registration Number
- NCT03371771
- Locations
- πΊπΈ
Greenwood Senior Center, Seattle, Washington, United States
πΊπΈWallingford Senior Center, Seattle, Washington, United States
πΊπΈSoutheast Senior Center, Seattle, Washington, United States
Text Message Intervention to Improve Cardiac Rehab Participation
Not Applicable
Terminated
- Conditions
- Myocardial InfarctionHeart TransplantChronic Stable Heart FailureCoronary Artery Bypass SurgeryHeart Valve Repair or ReplacementPercutaneous Coronary InterventionLeft Ventricular Assist DeviceChronic Stable Angina
- Interventions
- Behavioral: Text Messaging Intervention
- First Posted Date
- 2017-11-17
- Last Posted Date
- 2018-07-12
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 38
- Registration Number
- NCT03346278
- Locations
- πΊπΈ
University of Washington Medical Center, Seattle, Washington, United States
A Phase 2A Evaluation of the Safety, Tolerability, Pharmacokinetics, Efficacy of Clofazimine (CFZ) in Cryptosporidiosis
- First Posted Date
- 2017-11-14
- Last Posted Date
- 2019-08-13
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 33
- Registration Number
- NCT03341767
- Locations
- π²πΌ
Malawi-Liverpool-Wellcome Trust Clinical Research Programme (MLW), Blantyre, Malawi
The Use of Belladonna and Opium Suppository in the Treatment of Postoperative Stent Pain
Phase 4
Completed
- Conditions
- Nephrolithiasis
- Interventions
- Other: Placebo suppository
- First Posted Date
- 2017-11-06
- Last Posted Date
- 2023-06-18
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 71
- Registration Number
- NCT03332056
Doxorubicin Hydrochloride, Pembrolizumab, Vinblastine, and Dacarbazine in Treating Patients With Classical Hodgkin Lymphoma
Phase 1
Active, not recruiting
- Conditions
- Classical Hodgkin Lymphoma
- Interventions
- Other: Laboratory Biomarker Analysis
- First Posted Date
- 2017-11-06
- Last Posted Date
- 2025-01-09
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 50
- Registration Number
- NCT03331341
- Locations
- πΊπΈ
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Β© Copyright 2025. All Rights Reserved by MedPath